Silodosin is NOT Indicated for Use in Females
Silodosin is explicitly not indicated for use in females according to the FDA drug label, which clearly states in multiple sections that "Silodosin is not indicated for use in females" 1. This represents the highest level of regulatory guidance and must take precedence over any exploratory research.
Regulatory Position vs. Emerging Research
The FDA labeling is unequivocal: silodosin has no approved indication for female patients. The drug was developed, studied, and approved exclusively for benign prostatic hyperplasia (BPH) in males 1.
However, there is a notable disconnect between regulatory approval and emerging clinical research:
Recent Research Findings (Off-Label Use)
Despite the lack of FDA indication, several recent studies have explored silodosin in female populations:
Most recent evidence (2025): A prospective study of 85 females with moderate-to-severe LUTS showed significant improvements in IPSS (18.65 to 12.54), quality of life, overactive bladder symptoms, maximum flow rate, and residual urine volume over 12 weeks, with good tolerability 2.
Neurogenic bladder (2015): In 82 patients with neurogenic bladder (not gender-specific but included females), silodosin improved voiding symptoms, though this was an open-label study 3.
Combination therapy (2024): Silodosin plus solifenacin showed superior outcomes compared to solifenacin alone in 287 females with overactive bladder, particularly for reducing post-void residual 4.
Critical Limitations
These studies represent off-label, exploratory research with significant methodological constraints:
- Open-label designs without placebo controls in some cases
- Small sample sizes
- Single-center studies
- No FDA review or approval for safety/efficacy in females
- Unknown long-term safety profile in female populations
Guideline Context for Neurogenic Bladder
The 2021 AUA/SUFU guideline on neurogenic lower urinary tract dysfunction recommends alpha-blockers (as a class) to improve bladder emptying in NLUTD patients 5. However, this is a conditional recommendation with Grade C evidence, and the guideline does not specifically address silodosin or make gender-specific recommendations for alpha-blocker use.
Clinical Reality
For females with neurogenic bladder and bladder outlet obstruction, silodosin cannot be recommended as standard therapy given the explicit FDA contraindication for use in females. If alpha-blockade is considered appropriate based on clinical judgment:
- Use FDA-approved alternatives that have been studied in females (though most alpha-blockers share similar off-label status in women)
- Document informed consent regarding off-label use
- Monitor closely for orthostatic hypotension and other adverse effects
- Consider the lack of established dosing, safety, and efficacy data in females
Common Pitfall to Avoid
Do not assume that promising research findings override regulatory guidance. The FDA's explicit statement that silodosin is "not indicated for use in females" reflects the absence of adequate safety and efficacy data in this population, regardless of mechanistic plausibility or small exploratory studies.